How EMPAVELI can help | LDH
Changes in LDH with EMPAVELI
Rapid and sustained LDH reductions with EMPAVELI vs control arm—in people who had never received a C5i By Week 2 in PRINCE, average LDH levels in the EMPAVELI group had dropped from baseline and remained there through 26 weeks.
Louis is an adult with PNH taking EMPAVELI.
In people who had never received a C5i (PRINCE)
*Control arm (excluding C5i) only includes data on or before escape (switching to EMPAVELI).
At Week 26, average reductions in LDH levels were: -1870 U/L in the EMPAVELI group -400 U/L in the control arm (excluding C5i)
Changes in LDH levels with EMPAVELI vs eculizumab— in people who had previously received a C5i (PEGASUS) At Week 16 in PEGASUS, it could not be determined if EMPAVELI was any worse than C5i (eculizumab) in reducing LDH.
IMPORTANT SAFETY INFORMATION (cont’d) If you stop taking EMPAVELI, your healthcare provider will need to monitor you closely for at least 8 weeks after stopping EMPAVELI. Stopping treatment with EMPAVELI may cause a breakdown of red blood cells due to PNH. Symptoms or problems that can happen due to red blood cell breakdown include: decreased hemoglobin level in your blood
tiredness pain in the stomach (abdomen) blood clots erectile dysfunction (ED)
C5i=C5 inhibitor; LDH=lactate dehydrogenase; PNH=paroxysmal nocturnal hemoglobinuria; SE=standard error.
blood in your urine shortness of breath trouble swallowing
Please see full Important Safety Information, including Boxed WARNING regarding risk of serious infections, on pages 38-39, and the full Prescribing Information and Medication Guide.
16
17
Made with FlippingBook flipbook maker